Who's speaking at this Webinar?
Eric Carlson, Ph.D.
President and CEO, Protein Metrics Inc.
Chief Technology Officer, Intabio, Inc.
VP CMC, Coagulant Therapeutics Corporation
Testing is required to monitor modifications in biopharmaceutical development, from clone selection to manufacturing. However, current testing approaches for intact proteins are time-consuming and don’t provide real-time analytics to drive decision making.
In this webinar, Eric Carlson, President and CEO of Protein Metrics, will demonstrate how the Byos® Vendor-neutral Mass Spec Analysis platform, enables efficient analysis of Intact data for Critical Quality Attributes (CQAs). Erik Gentalen will share how Intabio’s Blaze platform utilizes microfluidic icIEF technology coupled with mass spectrometry to characterize intact protein charge variant with 100-fold higher throughput at a fraction of the cost of traditional approaches.
John Teare, VP, Biological Development & Manufacturing at Coagulent Therapeutics, will discuss how his company is using these technologies for some of the most challenging research: coagulation factors for bleeding disorders.
From this webinar, you will learn how to:
• Achieve high throughput analysis of biologics
• Efficiently analyse charge variants in biologics development
• Achieve high throughput CQAs (Critical Quality Attributes) monitoring
• Work with multiple mass spec vendors
• Speed up the development of biopharmaceuticals and therapeutic proteins
Like what you just read? You can find similar content on the communities below.Analysis & Separations Biopharma Cancer Research Cell Science Drug Discovery Proteomics & Metabolomics Immunology & Microbiology
To personalize the content you see on Technology Networks homepage, Log In or Subscribe for FreeLOGIN SUBSCRIBE FOR FREE